Antiviral treatment after liver cancer surgery
Part of Cancer, Digestive system, Infections clinical trials.
This trial tests whether continuing antiviral therapy after surgery for hepatitis B-related liver cancer can improve outcomes. It focuses on patients with early-stage disease, good liver function, and no prior cancer treatments other than surgery or ablation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have hepatitis B (positive for HBsAg).
- You have been diagnosed with liver cancer and treated with surgery or a procedure called ablation.
- Your liver cancer is at an early stage (BCLC 0 or A).
- Your liver function is good (Child-Pugh A).
- You have not had other cancer treatments like chemotherapy, targeted therapy, immune therapy, or a liver transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
This trial tests whether a targeted chemotherapy infusion directly into the liver's main artery (HAIC) after surgery can prevent liver cancer from coming back. It is for people with certain high-risk features, like a large tumor or cancer in blood vessels, who have had their tumor completely removed.
This trial studies an antiviral medicine given after surgery for liver cancer to help prevent the cancer from coming back. It focuses on people who are hepatitis B–positive (HBsAg positive) and have complete remission on follow-up checks.
This trial tests a new two-drug combination for people with chronic hepatitis B who have had their liver cancer completely removed. The goal is to see if the combination can better control the hepatitis B virus.
This study tests an added hepatitis B immune medicine (HBV immunoglobulin) in people with chronic hepatitis B who have liver cancer and are planning surgery or a liver transplant. The goal is to see if giving this protection around the time of treatment can help prevent liver cancer from coming back or worsening.
This early-stage trial tests whether a drug called pegylated interferon alpha-2β can help prevent hepatitis B-related liver cancer from coming back after surgery. The drug aims to boost your immune system to fight any remaining cancer cells.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.